ClinicalTrials.gg
Not yet recruitingNCT07683923SCAD-ALIGNUpdated Oct 16, 2026

Spontaneous Coronary Artery Dissection - AntipLatelet Therapy Intensity in Guided coNservative Management (SCAD-ALIGN) Trial

A Phase 4 interventional study of Acetylsalicylic acid ASA and ASA plus Clopidogrel in SCAD and ACS (Acute Coronary Syndrome), sponsored by Universitätsklinikum Hamburg-Eppendorf. Not yet recruiting at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Phase 4, Interventional, and Treatment

How we know

Updated Oct 16, 2026Eligibility revisedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,518
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing aspirin in Acute Coronary Syndrome — 7 open to participants now, 8 under way, 1 of them phase 3. Aspirin · Acute Coronary Syndrome.

Planned enrollment
4th of 26
3,518 · median 200
Started
2027
with 1 other
Phase 4
17 of 26
4 open now
Registered
24th of 26
by date

Among the 26 studies testing aspirin in Acute Coronary Syndrome, this one is the 4th largest by planned enrollment, is one of 2 that started in 2027, is one of 17 in phase 4, and was the 24th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

7 of the 26 studies testing aspirin in Acute Coronary Syndrome are open now, in 8 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing aspirin in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

Spontaneous coronary artery dissection (SCAD) is a rare cause of acute coronary syndrome in which blood flow to the heart muscle is reduced or interrupted. It predominantly affects women between 30 and 55 years of age and typically occurs in the absence of atherosclerosis. For many years, SCAD remained underdiagnosed and has only recently been more systematically recognised. The SCAD-ALIGN trial will be the first randomised study to systematically compare two antiplatelet treatment strategies in patients with SCAD.

SCAD is usually not associated with significant atherosclerosis or the classic vessel occlusion caused by a blood clot. Instead, bleeding occurs within the wall of a coronary artery, causing the vessel layers to separate and thereby impairing or completely obstructing blood flow. Patients develop symptoms of acute myocardial infarction, such as chest pain, shortness of breath, or nausea. A characteristic feature is that these symptoms often occur in individuals without a prior history or risk of heart disease.

Platelets play a crucial role in blood clotting but can also accumulate inside blood vessels and further impair flow. Antiplatelet medications are used to prevent this. In current clinical practice, SCAD patients are often treated according to general guidelines for acute coronary syndrome, which typically include two different antiplatelet therapies, a strategy developed and tested in older patients with proven atherosclerosis.

The SCAD-ALIGN trial is based on a fundamental difference between SCAD and classic heart attacks. In typical heart attacks, a blood clot usually blocks a vessel, and after the implantation of a vascular support device ("stent"), intensive antiplatelet therapy is used to prevent further clot formation. In SCAD, however, the underlying problem is a tear or bleeding within the vessel wall. In this situation, intensive antiplatelet therapy could delay the resolution of the bleeding or even worsen it, thereby adversely affecting the course of the disease. The study will therefore investigate whether a less intensive treatment strategy may be more beneficial in these patients.

The SCAD-ALIGN trial compares two treatment strategies: moderate antiplatelet therapy with a single medication for three months versus more intensive therapy with two agents for three months, followed by nine months of treatment with a single medication. The primary endpoint is a composite of recurrent myocardial ischemia, recurrent SCAD, myocardial infarction, the need for revascularization, and death.

The SCAD-ALIGN trial is part of the Multinational Clinical Trials Initiative of the Global Cardiovascular Research Funders Forum (GCRFF). The study is designed as an international, multicentre, randomised, open-label clinical trial. Because SCAD is a rare condition, close collaboration across national borders is essential. The results are expected to make an important contribution to the development of evidence-based treatment recommendations for SCAD, improve care and quality of life for patients worldwide.

Read the detailed description

Spontaneous Coronary Artery Dissection (SCAD) is an important cause of acute coronary syndromes (ACS), predominantly in younger women. Evidence to guide optimal antiplatelet therapy is limited. Although dual antiplatelet therapy (DAPT) is commonly prescribed, observational studies have linked DAPT to higher rates of adverse cardiovascular events in conservatively managed SCAD. The SCAD-ALIGN trial is an international, prospective, randomized, open-label, group-sequential adaptative, blinded endpoint-adjudicated with two-parallel groups, multicenter trial comparing an intensive APT strategy versus a moderate APT strategy in patients with ACS due to SCAD who are treated conservatively, i.e., without revascularization. The SCAD-ALIGN study will define the benefit-risk balance of these strategies, inform international guideline committees, and clarify optimal treatment strategies. To demonstrate the superiority of a moderate intensity APT strategy compared to an intensive treatment regimen in patients presenting with an ACS caused by SCAD with planned conservative management with regard to major adverse cardiovascular events (MACE), a composite endpoint consisting of all-cause mortali-ty, myocardial infarction, recurrent SCAD, unplanned coronary revascularization, ischemic stroke, or transient ischemic attack 12 months after randomization was chosen.

03

Conditions studied

  • SCAD
  • ACS (Acute Coronary Syndrome)

Keywords

  • SCAD
  • ACS
  • APT
  • MACE
  • DAPT
  • spontaneous coronary artery dissection
  • Antiplatelet therapy
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Presentation with an Acute Coronary Syndrome.
  3. Suspected SCAD on coronary angiography (determined by the local investigator).
  4. Planned conservative treatment of SCAD.
  5. Ability to understand the patient information and to personally sign and date the to participate in the trial, before completing any trial-related procedures.
  6. The patient is cooperative and available for the entire trial.
  7. Written and informed consent.

9. For women of : Patient is willing to use adequate precautions during the study (until 12 Month FU)

Exclusion criteria

Exclusion Criteria:

  1. Any to DAPT (ASA and clopidogrel)
  2. Any indication for APT (including thienopyridines, non-thienopyridines, ASA and other anti-thrombotic agents) other than SCAD.
  3. Recurrent SCAD within 90 days in the index vessel.
  4. Known pregnancy
  5. Current participation in another clinical trial with drugs or medicinal products.
  6. Previous participation in SCAD-ALIGN
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
3,518 participants (estimated)

Study arms

  • Experimental
    moderate APT

    moderate APT therapy, defined as 3 months ASA followed by cessation of APT

    Drug: Acetylsalicylic acid ASA

  • Active comparator
    intensive APT

    intensive APT therapy, defined as 3 months DAPT (ASA + clopidogrel), followed by 9 months of clopidogrel monotherapy

    Drug: ASA plus Clopidogrel

Interventions

  • DrugAspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3 months ASA monotherapy, dose accoring to international guidelines and local Standard of Care

  • DrugASA plus Clopidogrel

    Drug pages: AspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ClopidogrelStudies of ClopidogrelClopidogrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3 months ASA + clopidgrel DAPT, followed by 9 months of clopidogrel monotherapy, doses accoring to international guidelines and local Standard of Care

06

What researchers measure

Primary outcomes

  1. MACE (Major Adverse Cardiovascular Events) with all-cause-mortality

    MACE as a composite of all-cause mortality, myocardial infarction, recurrent SCAD, unplanned coronary revascularization, ischemic stroke, or transient is-chemic attack

    Time frame: 12 months follow-up

Secondary outcomes

  1. First secondary endpoint: MACE (Major Adverse Cardiovascular Events) with cardiovascular mortality

    Composite endpoint consisting of cardiovascular mortality, myocardial infarction, recurrent SCAD, unplanned coronary revascularization, ischemic stroke, or transient ischemic attack

    Time frame: 12 months follow-up

  2. second secondary endpdoint: NACE (Net adverse clinical events)

    composite of cardiovascular mortality, myocardial infarction, recurrent SCAD, unplanned coronary revascularization, ischemic stroke or transient ischemic attack and Bleeding aca-demia research consortium (BARC) bleeding types 3 or 5

    Time frame: 12 months follow-up

  3. MACE

    composite endpoint consisting of cardiovascular mortality, myocardial infarction, recurrent SCAD, unplanned coronary revascularization, ischemic stroke, or transient ischemic attack

    Time frame: 3 Months follow-up

  4. all-cause mortality

    Time frame: 3 months FU

  5. all-cause mortality

    Time frame: 12 months FU

  6. cardiovascular mortality

    Time frame: 3 months FU

  7. cardiovascular mortality

    Time frame: 12 months FU

  8. myocardial infarction

    Time frame: 3 months FU

  9. myocardial infarction

    Time frame: 12 months FU

  10. recurrent SCAD

    Time frame: 3 months FU

  11. recurrent SCAD

    Time frame: 12 months FU

  12. unplanned coronary revascularization

    Time frame: 3 months FU

  13. unplanned coronary revascularization

    Time frame: 12 months FU

  14. ischemic stroke

    Time frame: 3 months FU

  15. ischemic stroke

    Time frame: 12 months FU

  16. transient ischemic attack

    Time frame: 3 months FU

  17. transient ischemic attack

    Time frame: 12 months FU

  18. NACE

    composite of cardiovascular mortality, myocardial infarction, recurrent SCAD, unplanned coronary revascularization, ischemic stroke or transient ischemic attack and BARC bleeding types 3 or 5

    Time frame: 3 months FU

  19. BARC bleeding type 1, 2, 3 or 5

    Time frame: 3 months FU

  20. BARC bleeding type 1, 2, 3 or 5

    Time frame: 12 months FU

  21. Menorrhagia associated quality of life

    assessed with Menorrhagia multi-attribute scale (MMAS), consisting of 6 dimensions with 4-level Likert scale for responses

    Time frame: 3 months FU

  22. Menorrhagia associated quality of life

    assessed with Menorrhagia multi-attribute scale (MMAS), consisting of 6 dimensions with 4-level Likert scale for responses

    Time frame: 12 months FU

  23. MACE

    composite endpoint consisting of all-cause mortality, myocardial infarction, recurrent SCAD, unplanned coronary revascularization, ischemic stroke, or transient ischemic attack

    Time frame: 3 Months follow-up

  24. Health-related Quality of Life

    assessed with EQ5D-5L questionnaire, consisting of 5 domains with 5-level Likert scale and a visual analogue self-rating scale (VAS) from 0 (worst) to 100 (best)

    Time frame: 3 months FU

  25. Health-related Quality of Life

    assessed with EQ5D-5L questionnaire, consisting of 5 domains with 5-level Likert scale and a visual analogue self-rating scale (VAS) from 0 (worst) to 100 (best)

    Time frame: 12 months FU

  26. Patient Health Questionnaire PHQ-8

    self-administered version of the Primary Care Evaluation of Mental Disorders diagnostic Instrument for common mental disorders. The PHQ-8 is the depression module, which scores each of the 8 diagnostic criteria for major depression in Diagnostic and Statistical Manual Fourth Edition using a 4-level Likert scale

    Time frame: 3 months FU

  27. Patient Health Questionnaire PHQ-8

    self-administered version of the Primary Care Evaluation of Mental Disorders diagnostic Instrument for common mental disorders. The PHQ-8 is the depression module, which scores each of the 8 diagnostic criteria for major depression in Diagnostic and Statistical Manual Fourth Edition using a 4-level Likert scale

    Time frame: 12 months FU

  28. Generalized Anxiety Disorder (GAD-7) questionnaire

    screening tool to identify probable cases of GAD and to assess symptom severity. 7 items and 4-level Likert-scale

    Time frame: 3 months FU

  29. Generalized Anxiety Disorder (GAD-7) questionnaire

    screening tool to identify probable cases of GAD and to assess symptom severity. 7 items and 4-level Likert-scale

    Time frame: 12 months FU

07

Study locations

5 sites
  • Division of Cardiology, Vancouver General Hospital, University of British Columbia
    Vancouver, British Columbia V5Z 1M9, Canada
  • University Medical Center Hamburg-Eppendorf
    Hamburg, Free and Hanseatic City of Hamburg 20246, Germany
  • Division of Cardiology, St. Antonius Hospital
    Nieuwegein, 3435 CM, Netherlands
  • Department of Cardiology and Department of Medical and Health Sciences, Linköping University
    Linköping, SE-581 83, Sweden
  • University Hospitals of Leicester NHS Trust
    Leicester, LE1 5WW, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided — to be determined as global study with various stakeholders and country-specific requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Feb 2033, 71 months later.

Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 71 months is above that.

Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jul 6, 2026
StartEst.
Mar 1, 2027
Primary completionEst.
Feb 28, 2033
CompletionEst.
Feb 28, 2033
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited, 1 removed; 1 exclusion criterion edited, 3 added, 11 removed
What changed in the criteria
Inclusion criteria
  • RemovedIntensive as well as moderate treatment of SCAD is possible.
  • EditedAbility to understand the patient information and to personally sign and date the informed consent to participate in the studytrial, before completing any studytrial-related procedures.
  • EditedThe patient is cooperative and available for the entire studytrial.
Exclusion criteria
  • RemovedHypersensitivity to the study medication.
  • RemovedAny indication for oral anticoagulation.
  • AddedAny contraindication to DAPT (ASA and clopidogrel)
  • RemovedCardiogenic shock at the time of screening.
  • RemovedCoronary artery disease (CAD) requiring secondary preventive therapy with APT.
  • RemovedLife threatening bleeding (BARC type ≥3) at the time of screening.
  • RemovedActive bleeding, such as peptic ulcer, tumor bleeding or intracranial hemor-rhage at the time of screening.
  • RemovedHistory of major bleeding, BARC class ≥3 within 3 months before study in-clusion.
  • RemovedKnown bleeding diathesis.
  • RemovedKnown coagulopathy or refusal of blood transfusion.
  • RemovedPlanned surgery or intervention at high bleeding risk during the study period.
  • RemovedCo-administration of contraindicated medications as follows: other P2Y12 inhibitors (prasugrel or ticagrelor); anticoagulants (warfarin, new oral antico-agulants, or chronic therapy with subcutaneous anticoagulants); cytochrome P450 2C19 inhibitors (fluoxetine, moclobemid or voriconazole); probenecid; high dose of methotrexate (≥15 mg/week); lithium.
  • AddedRecurrent SCAD within 90 days in the index vessel.
  • EditedKnown pregnancy or lactation.
  • AddedPrevious participation in SCAD-ALIGN
Oct 16, 2026
Sponsor
Collaborators added: Davos Life Science Pte Ltd; collaborators removed: Cardio-CARE AG, Davos
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Eligibility 2 inclusion criteria edited, 1 removed; 1 exclusion criterion edited, 3 added, 11 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedIntensive as well as moderate treatment of SCAD is possible.
    • EditedAbility to understand the patient information and to personally sign and date the informed consent to participate in the studytrial, before completing any studytrial-related procedures.
    • EditedThe patient is cooperative and available for the entire studytrial.
    Exclusion criteria
    • RemovedHypersensitivity to the study medication.
    • RemovedAny indication for oral anticoagulation.
    • AddedAny contraindication to DAPT (ASA and clopidogrel)
    • RemovedCardiogenic shock at the time of screening.
    • RemovedCoronary artery disease (CAD) requiring secondary preventive therapy with APT.
    • RemovedLife threatening bleeding (BARC type ≥3) at the time of screening.
    • RemovedActive bleeding, such as peptic ulcer, tumor bleeding or intracranial hemor-rhage at the time of screening.
    • RemovedHistory of major bleeding, BARC class ≥3 within 3 months before study in-clusion.
    • RemovedKnown bleeding diathesis.
    • RemovedKnown coagulopathy or refusal of blood transfusion.
    • RemovedPlanned surgery or intervention at high bleeding risk during the study period.
    • RemovedCo-administration of contraindicated medications as follows: other P2Y12 inhibitors (prasugrel or ticagrelor); anticoagulants (warfarin, new oral antico-agulants, or chronic therapy with subcutaneous anticoagulants); cytochrome P450 2C19 inhibitors (fluoxetine, moclobemid or voriconazole); probenecid; high dose of methotrexate (≥15 mg/week); lithium.
    • AddedRecurrent SCAD within 90 days in the index vessel.
    • EditedKnown pregnancy or lactation.
    • AddedPrevious participation in SCAD-ALIGN
    Sponsor Collaborators added: Davos Life Science Pte Ltd; collaborators removed: Cardio-CARE AG, Davos
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07683923
Collaborators
National Institute for Health Research Leicester Biomedical Research Centre, Leicester, UK, Gesellschaft für Therapieforschung mbH, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Davos Life Science Pte Ltd
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Feb 28, 2033 (estimated)
Completion
Feb 28, 2033 (estimated)
Last update
Oct 16, 2026

Study contacts

Stefan Blankenberg, MD
Contact
s.blankenberg@uke.de
+49 407410 ext. 53972
Jane A. Leopold, MD
Contact
jleopold@bwh.harvard.edu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion